gevokizumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
Nov 1, 2014 → Feb 1, 2016
NCT ID
NCT02318914About gevokizumab
gevokizumab is a phase 3 stage product being developed by XOMA for Pyoderma Gangrenosum. The current trial status is terminated. This product is registered under clinical trial identifier NCT02318914. Target conditions include Pyoderma Gangrenosum.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02318914 | Phase 3 | Terminated |
| NCT01950312 | Phase 2 | Completed |
| NCT01882504 | Phase 2 | Completed |
| NCT02293564 | Pre-clinical | Completed |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| sisomicin | Merck | Approved | 85 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 52 |
| Secukinumab | Novartis | Phase 1/2 | 41 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 32 |
| gevokizumab | XOMA | Phase 2 | 44 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 69 |
| vilobelimab | InflaRx | Phase 2 | 44 |